EGID Biopsies Have Functionally Distinct and Activated Mast Cells That Contribute to Disease Pathogenesis and Are Inhibited By an Anti-Siglec-8 Antibody, Antolimab (AK002)


Melina Butuci PhD<sup>1</sup>, Julia Schanin PhD<sup>1</sup>, Emily C. Brock MS<sup>1</sup>, Henrik S. Rasmussen MD PhD<sup>1</sup>, Bhupinder Singh MD<sup>1</sup>, Richard Drake<sup>2</sup>, Kathryn Peterson MD<sup>2</sup>, and <u>Bradford A. Youngblood PhD<sup>1</sup></u>

<sup>1</sup>Allakos, Inc., Redwood City, CA.; <sup>2</sup>University of Utah, Salt Lake City, UT



DDW 2020 Chicago, IL May 2<sup>nd</sup> – 5<sup>th</sup> 2020

## Eosinophilic Gastrointestinal Diseases (EGIDs)




#### EoE, EG, EoD

## Chronic Eosinophilic Inflammation of the Esophagus, Stomach, or Duodenum

- Eosinophils and mast cells are important drivers of disease
- Symptoms: abdominal pain, nausea, early satiety, loss of appetite, bloating, abdominal cramping, vomiting, diarrhea, and dysphagia
- No FDA approved treatment for EoE, EG, or EoD
- Current standard of care: diet and/or steroids




## Eosinophils and Mast Cells Drive EGID Pathogenesis



- EGIDs are characterized by antigen-mediated eosinophil and mast cell infiltration in the esophagus (EoE), stomach (EG), and duodenum (EoD)
- Despite the evidence of mast cell involvement in EGIDs, the mechanism by which they contribute to disease pathogenesis has yet to be established in human tissue



## Antolimab Targets Siglec-8 on Eosinophils & Mast Cells






# Eosinophils and Mast Cells Are Increased in EoE, EG, and EoD Biopsies

#### Esophageal Tissue


#### **Gastric Tissue**



#### Increased numbers of eosinophils and mast cells are found across EGIDs




## Mast Cells Are Activated in Upper and Lower EGIDs



Mast cell activation is seen in EoE, EG, and EoD biopsies




### Gating Strategy and Method for Sorting and Activating Mast Cells from GI Tissue






## EoE, EG, and EoD Mast Cells Basally Produce Th2 Inflammatory Mediators



Mast cells from EGID tissue have a functionally distinct cytokine profile




### EGID Tissue Mast Cells Produce Increased Levels of Inflammatory Cytokines Upon Stimulation



#### Mast Cells

# Antolimab Inhibits Cytokine Production Induced by IgE/FccRI Activation of EGID Biopsy Mast Cells





## Summary

- Elevated and activated mast cells are found across EGIDs, including EoE, EG, and EoD
- Mast cells from EGID tissue basally produce Th2 cytokines that are associated with T cell activation and eosinophil and mast cell recruitment
- Upon stimulation, EGID mast cells produce higher levels of mediators compared to nondiseased GI tissue mast cells, suggesting mast cells from EGID tissue have increased pathogenic potential
- IgE/FccRI activation of EGID tissue mast cells induces mediator production that is inhibited by antolimab
- Targeting both mast cells and eosinophils may be needed to significantly reduce inflammation in EGIDs

